Unknown

Dataset Information

Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons.


ABSTRACT: Dual antiplatelet therapy simultaneously blocks different platelet activation pathways and might thus be more potent at inhibiting platelet activation and more effective at reducing major ischemic vascular events compared to antiplatelet monotherapy. Aspirin plus clopidogrel dual therapy is now the standard therapy for patients with acute coronary syndrome and for those undergoing percutaneous coronary intervention. However, dual antiplatelet therapy carries an increased risk of bleeding. Patients with ischemic stroke or transient ischemic attack (TIA) are generally older and likely to have a fragile cerebrovascular bed, which further increases the risk of systemic major bleeding events and intracranial hemorrhage. Clinical trials and meta-analyses suggest that in comparison to antiplatele

SUBMITTER: Hong KS 

PROVIDER: S-EPMC4101094 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature